Home > Boards > US Listed > Biotechs > Cel-Sci (CVM)

Funny how everyone loves Geert, then in one

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Spideyboy Member Profile
 
Followed By 11
Posts 872
Boards Moderated 0
Alias Born 04/07/08
160x600 placeholder
CEL-SCI Awarded European Patent for LEAPS Vaccine in Treatment of Rheumatoid Arthritis Business Wire - 9/18/2020 9:00:00 AM
CEL-SCI Corporation Issues Letter to Shareholders Business Wire - 9/15/2020 9:15:00 AM
CEL-SCI Corporation to Present at H.C. Wainwright 22nd Annual Global Investment Conference Business Wire - 9/11/2020 9:00:00 AM
CEL-SCI Corporation Reports Third Quarter Fiscal 2020 Financial Results Business Wire - 8/11/2020 8:30:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/10/2020 5:27:09 PM
CEL-SCI Announces Early Results with COVID 19 LEAPS Vaccine/Treatment Business Wire - 7/24/2020 8:30:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 7/13/2020 6:03:54 AM
Securities Registration Statement (s-1) Edgar (US Regulatory) - 7/2/2020 5:39:35 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2020 10:37:54 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2020 10:36:13 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/1/2020 10:34:55 AM
CEL-SCI Corporation Receives $10 Million Through Warrant Exercises Business Wire - 6/30/2020 8:30:00 AM
CEL-SCI to Present at H.C. Wainwright Virtual Fireside Chat Series Business Wire - 6/24/2020 10:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) Edgar (US Regulatory) - 5/26/2020 5:24:16 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/26/2020 5:23:10 PM
CEL-SCI Corporation Reports Second Quarter Fiscal 2020 Financial Results Business Wire - 5/11/2020 8:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/8/2020 5:04:18 PM
CEL-SCI’s Pivotal Phase 3 Study Has Reached the Required Number of Events to Evaluate Data for Multikine in Treatment of He... Business Wire - 5/4/2020 7:15:00 AM
Securities Registration: Employee Benefit Plan (s-8) Edgar (US Regulatory) - 4/24/2020 5:50:15 PM
CEL-SCI Reports Recent Data Review by the Independent Data Monitoring Committee for Its Pivotal Phase 3 Head & Neck Cancer St... Business Wire - 4/23/2020 9:15:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 4/21/2020 6:01:11 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/20/2020 5:06:19 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/20/2020 5:03:20 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/20/2020 4:59:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/20/2020 4:56:22 PM
Spideyboy   Friday, 02/28/20 02:27:42 AM
Re: None
Post # of 33564 
Funny how everyone loves Geert, then in one day, people start hating on him and so many new posters come out of the cracks to talk trash or nonsense.

The situation with the company itself is unchanged (less funds though), so would everyone calm down.

If this keeps up though, we're going to need another dilution next month.

Last December they raised enough for 1 additional quarter and I mentioned we'd likely need another one, and given the price drop and the Covid-19 turmoil on the markets it is likely difficult to convince warrant holders to convert at the moment.

I was expecting the strategy to be to get to results on the last raise, assuming Cel-Sci does have an understanding of the total number of events thus far, otherwise why only raise 1 quarter's worth of cash, but perhaps if ZSBiotech is correct then a new time-point of May 2020 has been put forward. Either-way a new raise pre-results is looking more likely now. I don't see why Cel-Sci doesn't open an ATM. They could take when they want at the higher market prices, especially as they are clearly going to need significantly more cash, pre and/or post-results.

However yes we should still take it as good news that the trial is still ongoing. Either the drug is amazing, or there's been a big mess up with type of patient recruitment, but that shouldn't be the case. I don't buy the concern on drop-outs either as the IDMC ought to have mentioned something on that by now.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences